AcelRx Pharmaceuticals (ACRX) Getting Somewhat Favorable News Coverage, Study Shows

Media coverage about AcelRx Pharmaceuticals (NASDAQ:ACRX) has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 46.1802522301182 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news headlines that may have effected Accern’s scoring:

AcelRx Pharmaceuticals (NASDAQ ACRX) opened at $2.12 on Tuesday. The stock has a market capitalization of $106.97, a price-to-earnings ratio of -1.89 and a beta of 2.96. AcelRx Pharmaceuticals has a one year low of $1.55 and a one year high of $5.75. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78.

ACRX has been the subject of a number of research analyst reports. ValuEngine cut AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 15th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of AcelRx Pharmaceuticals in a research note on Tuesday, October 3rd. Roth Capital set a $8.00 target price on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 12th. Jefferies Group cut AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 13th. Finally, Royal Bank of Canada lowered their price objective on AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, October 13th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. AcelRx Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $6.18.

In related news, Director Mark G. Edwards acquired 30,000 shares of the stock in a transaction on Tuesday, November 14th. The stock was acquired at an average price of $1.90 per share, for a total transaction of $57,000.00. Following the completion of the purchase, the director now owns 150,000 shares of the company’s stock, valued at $285,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 28.10% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This piece was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2018/01/09/acelrx-pharmaceuticals-acrx-getting-somewhat-favorable-news-coverage-study-shows.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Insider Buying and Selling by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit